<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berdieke Goemaere</style></author><author><style face="normal" font="default" size="100%">Lagrou, Katrien</style></author><author><style face="normal" font="default" size="100%">Spriet, Isabel</style></author><author><style face="normal" font="default" size="100%">Marijke Hendrickx</style></author><author><style face="normal" font="default" size="100%">Eline Vandael</style></author><author><style face="normal" font="default" size="100%">Pierre Becker</style></author><author><style face="normal" font="default" size="100%">Boudewijn Catry</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systemic antifungal drug use in Belgium-One of the biggest antifungal consumers in Europe.</style></title><secondary-title><style face="normal" font="default" size="100%">Mycoses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antifungal Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Utilization</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">intensive care units</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycoses</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Jun</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">62</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Reports on the consumption of systemic antifungal drugs on a national level are scarce although of high interest to compare trends and the associated epidemiology in other countries and to assess the need for antifungal stewardship programmes.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;To estimate patterns of Belgian inpatient and outpatient antifungal use and provide reference data for other countries.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Consumption records of antifungals were collected in Belgian hospitals between 2003 and 2016. Primary healthcare data were available for the azoles for the period 2010-2016.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The majority of the antifungal consumption resulted from prescriptions of fluconazole and itraconazole in the ambulatory care while hospitals were responsible for only 6.4% of the total national consumption and echinocandin use was limited. The annual average antifungal consumption in hospitals decreased significantly by nearly 25% between 2003 and 2016, due to a decrease solely in non-university hospitals. With the exception of specialised burn centres, antifungals are mostly consumed at ICUs and internal medicine wards. A significant decline was also observed in the consumption of azoles in primary health care, attributed to itraconazole. The major part of azoles was prescribed by generalists followed by dermatologists.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;In spite of the downward trend in annual use of systemic antifungal drugs, Belgium remains one of the biggest consumers in Europe.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue></record></records></xml>